Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction.

"Disclosures:: J.A.C. is supported by NIH grants R01-HL 121510, R33-HL-146390, R01HL153646, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874, and R56-HL136730. He has recently consulted for Bayer, Sanifit, Fukuda-Denshi, Bristol Myers Squibb, JNJ, Edwards Life Sciences, Merck and the Galway-Mayo Institute of Technology. He received University of Pennsylvania research grants from the NIH, Fukuda-Denshi, Bristol Myers Squibb and Microsoft. He is named as an inventor in a University of Pennsylvania patent for the use of inorganic nitrates/nitrites in Heart Failure with Preserved Ejection Fraction. He has received research device loans from Atcor Medical, Fukuda-Denshi, Uscom, NDD Medical Technologies, Microsoft and MicroVision Medical. J.B.C. is supported by NIH grants K23-HL133843 and R01-HL153646.: PZ is supported by R01 HL155599, R01 HL157264, R01 HL149722, U01-HL160277, UH3DK128298. He also receives research support from Amgen. He has consulted for Pfizer and Vyaire. E.R. has received unrestricted educational grants from Amgen, Merck Sharp & Dohme, AstraZeneca, Sanofi and Unilever, speakers’ or consultancy fees from Daiichi Sankyo, Novonordisk, Boehringer Ingelheim, Servier, Amgen, Sanofi, Novartis and Teva; all paid directly to Ghent University. AMR is supported by grants from Singapore NMRC and the Health Research Council of New Zealand. He holds the NZ Heart Foundation Chair in Cardiovascular Studies. In kind support and research grants are received from Roche Diagnostics, Abbott Laboratories and Novo Nordisk. He is named on ~ 30 cardiovascular biomarker patents. D.G. acknowledges support by the British Heart Foundation Centre of Research Excellence at Imperial College London (RE/18/4/34215)"

"Sources of Funding The proteomics work in this study was funded by Bristol-Myers-Squibb. The PHFS was funded by NIH grant R01HL088577 (TC). TOPCAT (Treatment of Pre- served Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial research materials were obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the TOPCAT Trial or the National Heart, Lung, and Blood Institute. Dr. Chirinos is supported by NIH grants R01-HL 121510, R33-HL-146390, R01HL153646, R01-AG058969, 1R01-HL104106, P01-HL094307, R03-HL146874, and R56-HL136730."